Left ventricular hypertrabeculation (LVHT) risk calculator estimates the risk of major adverse cardiovascular events (MACE) within 5 years for patients with a definite LVHT diagnosis.
What is ABLE-SCORE?
It is a simplified and accurate point-based risk scoring system to predict 1-, 2- or 5-year risk of MACE in LVHT patients according to their baseline clinical, biological and echocardiographic presentation. The ABLE-SCORE has been developed from 429 consecutive LVHT patients who underwent thorough cardiac evaluation and long-term follow-up at the National Center of Cardiovascular Diseases, Fuwai Hospital in China between 2009 and 2020, and has been validated by the multicenter external validation cohorts at the First Hospital of China Medical University and West China Hospital Sichuan University between 2014 and 2022. Its aim is to identify high-risk LVHT patients with greater probability of experiencing life-threatening adverse events, and provide guidance for clinical decisions in routine practice.
NB: Please read all definitions below carefully to avoid invalid interpretation of results. Each parameter must be set, and any missing value will render the calculation invalid.
Definitions:
[1] Age at diagnosis: age at which LVHT was definitely diagnosed.
[2] NT-pro BNP: plasma level of N-terminal pro-brain natriuretic peptide.
[3] Left atrium enlargement: left atrial anteroposterior dimension over 3.8cm in females or 4.0cm in males by transthoracic echocardiography.
[4] Left-ventricular ejection fraction: calculated using the modified biplane Simpson's rule by transthoracic echocardiography.
[5] MACE is defined as a combination of the following clinical endpoints: (1) all-cause mortality; (2) heart transplantation or left ventricular assist device implantation; (3) cardiac resynchronization therapy implantation; (4) malignant arrhythmia: aborted sudden cardiac death, ventricular fibrillation, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator therapy; and (5) thromboembolism: embolic stroke, transient ischemic attack, embolic myocardial infarction, pulmonary embolism, or peripheral artery embolism.
Sources of Funding:
This work was supported by the National Natural Science Foundation of China (Grant No. 82000323) and the National Clinical Research Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences (Grant No. NCRC2020012).
Developed by:
Limin Liu, Ligang Ding, and Yan Yao
Cardiac Arrhythmia Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases,
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
